Showing results (131-140 of 236) with videos related to

Sort By:
Pageof 24
Anticancer Research|December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal FibroblastsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|October 28, 2020
Structural Origin and Surgical Complications of Peripheral SchwannomasHirotaka Yonezawa, Shinji Miwa, Norio Yamamoto, et al.
Anticancer Research|August 2, 2019
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse ModelTakashi Higuchi, Norihiko Sugisawa, Kentaro Miyake, et al.
Biochemical and Biophysical Research Communications|April 9, 2019
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse modelTakashi Higuchi, Kentaro Miyake, Hiromichi Oshiro, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancerMasuyo Miyake, Kentaro Miyake, Qinghong Han, et al.
Translational Oncology|July 14, 2020
Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survivalTakashi Higuchi, Norihiko Sugisawa, Jun Ho Park, et al.
Frontiers in Oncology|May 21, 2021
Osteosarcoma-Derived Small Extracellular Vesicles Enhance Tumor Metastasis and Suppress Osteoclastogenesis by miR-146a-5pYoshihiro Araki, Hisaki Aiba, Takeshi Yoshida, et al.
Cancer Medicine|April 20, 2023
Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasisYohei Asano, Norio Yamamoto, Satoru Demura, et al.
Hepato-Gastroenterology|August 12, 2011
Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapyShogo Ohkoshi, Satoshi Yamagiwa, Masahiko Yano, et al.
Pageof 24